Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-09-14
Butterfly Network, Inc.
Butterfly sells handheld ultrasound probes, cloud workflow software, and partner licensing built on its semiconductor Ultrasound-on-Chip platform.
ai healthcare medical devices semiconductors software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Portable Ultrasound Platform Chasing Better Revenue Quality
The opportunity is not just more handheld scanners. The real upside comes if a differentiated chip platform becomes a recurring workflow, compliance, and licensing business before valuation patience runs out.

Analysis

Thesis
Butterfly can more than double equity value by 2031 if it turns a differentiated handheld ultrasound chip platform into a broader recurring revenue stack—enterprise workflow, compliance-heavy software, home-care utility contracts, and repeatable embedded royalties—while AI mainly expands who can scan, where scans happen, and how much value accrues to its installed base.
Last Economy Alignment
Cheaper AI lowers training and interpretation friction, which expands handheld ultrasound usage, and Butterfly still controls the chip, device, and workflow surface. The limiter is that it has not yet proven default-status software or royalty capture at scale.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.2x (from 5 most recent analyses)
Reasoning
The upside case is a quality-of-revenue story more than a pure unit story. If Butterfly proves that enterprise workflow, compliance, home/community programs, and embedded royalties can sit on top of the same probe platform, investors can accept less dependence on one-time hardware sales and still support healthy equity compounding even with some multiple compression.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not whether Butterfly’s probe works; it does. The real risk is whether higher-quality revenue from enterprise workflow, compliance-heavy software, home/community care, and Embedded royalties arrives fast enough to outrun valuation gravity, partner lumpiness, procurement delays, and incumbent bundling.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.41
They control a specialized ultrasound chip plus the software and compliance layer around it, so cheaper AI makes the device easier to use and expands where it can be deployed. The risk is that hospitals may treat the software as a feature while partner clearances and government permissions slow the higher-margin mix shift.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$10.67
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case